Henry Schein
Henry Schein's revenue rose 4.0% to $13.2 billion in fiscal 2025. Its operating margin was 5.0%, about the same as 4.9% a year earlier. Free cash flow was $573 million, down 18.1%. It paid out $850 million in dividends and buybacks, 148% of free cash flow. The diluted share count fell 4.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 0.6% a year and net income fell 2.6% a year, as buybacks cut the share count by 26%.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Henry Schein yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Henry Schein's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Henry Schein's fiscal 2025 free cash flow of $573M, net cash of −$3.0B at December 27, 2025 and 122 million diluted shares, from its filings. The scenarios are fitted to Henry Schein: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 1.4% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 8%: 7% for a stable business (Health Care Distributors), plus 1 point as a smaller company, worth $9.7B; the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $84.51
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Henry Schein's earnings per share of $3.43 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 28×, the middle of Henry Schein's own P/E today, its peers' median and its sector's median (the Health Care median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 9%, 8% and 7%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $84.51
- Value at this multiple, against the last close
- —
- Henry Schein's P/E at the last close
- 24.6×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| BrightSpring Health ServicesBTSG | $58.88 | $1.66 | 35.5× |
| Cardinal HealthCAH | $251.54 | $7.23 | 34.8× |
| McKessonMCK | $992.87 | $37.31 | 26.6× |
| Henry ScheinHSIC | $84.51 | $3.43 | 24.6× |
| CencoraCOR | $330.00 | $13.47 | 24.5× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 118 | 117 | 171 | 122 | 156 |
| Debt incl. finance leases | 880 | 1,159 | 2,351 | 2,536 | 3,107 |
| Net debt (negative means net cash) | 762 | 1,042 | 2,180 | 2,414 | 2,951 |
| Net debt to EBITDA | 0.7x | 1.1x | 2.5x | 2.6x | 3.1x |
| Debt to equity | 0.3x | 0.3x | 0.6x | 0.8x | 1.0x |
| Interest coverage | 31.6x | 21.3x | 7.1x | 4.7x | 4.3x |
| Current ratio | 1.7x | 1.8x | 1.7x | 1.4x | 1.4x |
| Quick ratio | 0.9x | 0.9x | 1.0x | 0.8x | 0.8x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, 1 insider bought $691,900 of Henry Schein shares on the open market, and 5 insiders sold $8.6 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 11, 2026 | William K DanielDirector | Bought | 10,000 | $69.19 | $691,900 | Form 4 |
| Mar 19, 2026 | Thomas C PopeckCEO, Henry Schein Products | Sold | 1,355 | $72.79 | $98,630 | Form 4 |
| Mar 10, 2026 | Kurt P KuehnDirector | Sold | 2,844 | $78.96 | $224,562 | Form 4 |
| Mar 5, 2026 | Philip A LaskawyDirector | Sold | 2,844 | $80.36 | $228,544 | Form 4 |
| Mar 4, 2026 | Mark E MlotekEVP, Chief Strategic Officer | Sold | 5,925 | $80.80 | $478,758 | Form 4 |
| Mar 2, 2026 | Stanley M BergmanChairman, CEO, Director | Sold | 43,812 | $81.31 | $3.6 million | Form 4 |
| Feb 27, 2026 | Stanley M BergmanChairman, CEO, Director | Sold | 10,785 | $81.20 | $875,742 | Form 4 |
| Feb 26, 2026 | Stanley M BergmanChairman, CEO, Director | Sold | 38,346 | $81.01 | $3.1 million | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 5 of 9 | 6 of 9 | 6 of 9 |
| Accruals ratio | −0.9% | −4.4% | −2.9% |
Compare
Put Henry Schein side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Henry Schein | FY25 | 4.0% | 5.0% | 4.3% | 7.5% | 3.1x | 6 | |
| Cardinal Health | FY26 | 14.2% | 1.0% | 1.8% | — | 1.1x | 6 | Compare |
| Cencora | FY25 | 9.3% | 0.8% | 1.0% | — | 0.9x | 7 | Compare |
| McKesson | FY26 | 12.4% | 1.5% | 1.4% | — | 0.4x | 6 | Compare |
| BrightSpring Health Services | FY25 | 28.2% | 2.3% | 3.1% | 5.2% | 5.3x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 11,572 | 12,462 | 13,202 | 9,986 | 10,119 | 12,401 | 12,647 | 12,339 | 12,673 | 13,184 |
| Revenue growth | 8.9% | 7.7% | 5.9% | −24.4% | 1.3% | 22.6% | 2.0% | −2.4% | 2.7% | 4.0% |
| Gross profit | 3,226 | 2,747 | 2,911 | 3,091 | 2,816 | 3,674 | 3,831 | 3,860 | 4,016 | 4,105 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 772 | 670 | 601 | 718 | 535 | 852 | 747 | 615 | 621 | 653 |
| Net income | 507 | 406 | 536 | 695 | 404 | 631 | 538 | 416 | 390 | 398 |
| Diluted EPS (US$) | 3.10 | 2.57 | 3.49 | 4.65 | 2.82 | 4.45 | 3.91 | 3.16 | 3.05 | 3.27 |
| Diluted shares (millions) | 164 | 158 | 154 | 149 | 143 | 142 | 138 | 132 | 128 | 122 |
| Cash flow | ||||||||||
| Cash from operations | 643 | 546 | 685 | 654 | 599 | 710 | 602 | 500 | 848 | 712 |
| Capital expenditure | 70 | 62 | 71 | 76 | 49 | 79 | 96 | 147 | 148 | 139 |
| Free cash flow | 572 | 483 | 613 | 578 | 550 | 631 | 506 | 353 | 700 | 573 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 550 | 450 | 200 | 525 | 74 | 401 | 485 | 250 | 385 | 850 |
| Acquisitions | 229 | 181 | 53 | 656 | 60 | 571 | 158 | 955 | 230 | 199 |
| Stock-based compensation | 58 | 37 | 33 | 45 | 9 | 78 | 54 | 39 | 39 | 39 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 62 | 175 | 80 | 106 | 421 | 118 | 117 | 171 | 122 | 156 |
| Debt incl. finance leases | 781 | 924 | 1,964 | 757 | 699 | 880 | 1,159 | 2,351 | 2,536 | 3,107 |
| Total assets | 6,812 | 7,864 | 8,500 | 7,151 | 7,773 | 8,481 | 8,607 | 10,573 | 10,218 | 11,215 |
| Total liabilities | 3,352 | 4,207 | 4,647 | 3,234 | 3,460 | 3,805 | 3,936 | 5,420 | 5,381 | 6,421 |
| Shareholders' equity | 2,793 | 2,812 | 2,961 | 2,998 | 3,348 | 3,425 | 3,446 | 3,655 | 3,393 | 3,245 |
| Margins and ratios | ||||||||||
| Gross margin | 27.9% | 22.0% | 22.1% | 30.9% | 27.8% | 29.6% | 30.3% | 31.3% | 31.7% | 31.1% |
| Operating margin | 6.7% | 5.4% | 4.5% | 7.2% | 5.3% | 6.9% | 5.9% | 5.0% | 4.9% | 5.0% |
| Net margin | 4.4% | 3.3% | 4.1% | 7.0% | 4.0% | 5.1% | 4.2% | 3.4% | 3.1% | 3.0% |
| Free cash flow margin | 5.0% | 3.9% | 4.7% | 5.8% | 5.4% | 5.1% | 4.0% | 2.9% | 5.5% | 4.3% |
| Return on capital | 16.1% | 9.6% | 10.7% | 11.3% | 10.2% | 14.3% | 11.5% | 8.2% | 7.2% | 7.5% |
| Return on equity | 17.9% | 14.5% | 18.6% | 23.3% | 12.7% | 18.6% | 15.7% | 11.7% | 11.1% | 12.0% |
| Return on assets | 7.6% | 5.5% | 6.5% | 8.9% | 5.4% | 7.8% | 6.3% | 4.3% | 3.8% | 3.7% |
| Net debt to EBITDA | 0.8x | 0.9x | 2.5x | 0.7x | 0.4x | 0.7x | 1.1x | 2.5x | 2.6x | 3.1x |